Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers

Journal of Clinical Pharmacology

Volumn 45, Issue 9, 2005, Pages 1018-1024

  Hebert, Mary F ^a   Blough, David K ^a   Townsend, Robert W ^b,d   Allison, Mark ^c   Buell, Donald ^b   Keirns, James ^b   Bekersky, Ihor ^b,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c MDS Inc   (Canada)

^d Kos Pharmaceuticals Inc   (United States)

^e Quark Biotech Inc   (United States)

Author keywords

Drug interaction; Micafungin; Pharmacokinetics; Tacrolimus

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; MICAFUNGIN; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; EVALUATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; STEADY STATE; VOLUNTEER;

ADULT; ANTIFUNGAL AGENTS; CALCINEURIN; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPOPROTEINS; MALE; PEPTIDES, CYCLIC; TACROLIMUS;

EID: 23944447575     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005279274     Document Type: Article

References (15)

1. Sattler M, Guengerich FP, Yun C-H, Christians U, Sweing KF. Cytochrome P-450A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753-761.
2. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077-6080.
3. FDA advisory meeting for Cancidas (caspofungin acetate), January 10, 2001.
4. Dressler D, Bekersky I, Lee J, Tracewell WG, Kisicki J, Mekki Q. Effect of meal time on tacrolimus bioavailability. Clin Pharmcol Ther. 1996;59:151.
5. Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979;68:1071-1074.
6. Bauer LA, Gibaldi M. Computation of model-independent pharmacokinetic parameters during multiple dosing. J Pharm Sci. 1983;72:978-979.
7. Ullmann AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin. 2003;19:263-271.
8. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transplant Infect Dis. 2002;4:25-30.
9. Hebert MF, Townsend RW, Blough DK, Bekersky I. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2005;45:954-960.
10. Mycamine (micafungin sodium) for injection product labeling. Deerfield, Ill: Fujisawa Healthcare, Inc, 2005.
11. Dai Y, Dowling ALS, Isoherranen N, Hebert MF, Davis CL, Thummel KE. CYP3A5 polymorphism affects tacrolimus intrinsic clearance and the risk of renal dysfunction. Paper presented at: International Society for the Study of Xenobiotics; September 2004; Vancouver, British Columbia.
12. Dai Y, Iwanaga K, Lin Y, et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol. 2004;68:1889-1902.
13. Lin YS, Dowling ALS, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular Pharmacol. 2002;62:162-172.
14. Min DI, Ellingrod VL, Marsh S, McLeod H. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit. 2004;26:524-528.
15. Shimoeda S, Ohta S, Kobayashi H, et al. Analysis of blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus. Biol Pharm Bull. 2005;28:477-480.